ALPMY News and Press, Astellas Pharma Inc. ADR From 05/01/24

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire - Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs tar...

2024-05-01 13:54:38 ET Poseida Therapeutics ( NASDAQ: PSTX ) shares traded higher on Wednesday after the company and Japanese drugmaker Astellas ( OTCPK:ALPMY ) announced a partnership to develop and commercialize CAR-T cell therapies for cancer.... Read the full article o...

2024-04-26 18:00:03 ET Astellas Pharma Inc. (ALPMF) Q4 2023 Results Conference Call April 25, 2024 04:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and Investor Relations Officer Naoki Okamura - President and Chief Executive Office Yoshitsu...

Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...

2024-04-25 03:54:46 ET More on Astellas Pharma: Pfizer, Astellas first-line bladder cancer therapy accepted for review in China Astellas collaborates with Mass General Brigham for translational medicine Historical earnings data for Astellas Pharma Read the ...

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting PR Newswire XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurr...

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK...

2024-04-05 10:56:25 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen slips as accounting errors force restatements Ocugen shares make gains after US court dismisses class action lawsuits Seeking ...

2024-03-28 11:54:15 ET More on Astellas Pharma, Pfizer etc. Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns Pfizer Inc. (PFE) Leerink Partners Global Biopharma Conference 2024 - (Transcript) Pfizer: Seagen Acquisition Starting To Bea...

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - Pivotal trial found the enfo...